Choff H, et al. Prediction of a potentially productive dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling. Br J Clin Pharmacol. 2012 Feb; 73(2):219?1. [PubMed: 21762205] 19. Sarich TC, Connelly MA, Schranz DB, et al. A Phase 0 study from the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans. Int J Clin Pharmacol Ther. 2012 May 14. 20. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007 Feb; 27(two):257?0. 21. Sweetlove M. Phase III trial of dalcetrapib: discontinued due to lack of efficacy. Pharmaceutical Medicine. 2012; 26(4):253?.ten.2165/11631240-000000000-00000 22. Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their possible for the treatment of cardiovascular illnesses. Vasc Well being Danger Manag. 2012; 8:323?1. [PubMed: 22661899] 23. Masson D, Jiang XC, Lagrost L, et al. The function of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res. 2009 Apr; 50( Suppl):S201?. [PubMed: 19023137] 24. Barter PJ, Rye KA. Cholesteryl ester transfer protein (CETP) inhibition as a approach to lower cardiovascular risk. J Lipid Res. 2012 May 1. 25. Boekholdt SM, Kuivenhoven JA, Hovingh GK, et al. CETP gene variation: relation to lipid parameters and cardiovascular risk. Curr Opin Lipidol. 2004 Aug; 15(4):393?. [PubMed: 15243211] 26. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary danger.1,7-Dibromoheptane structure JAMA.Formula of Ursocholic acid 2008 Jun 18; 299(23):2777?8. [PubMed: 18560005] 27. Brown ML, Inazu A, Hesler CB, et al. Molecular basis of lipid transfer protein deficiency within a household with enhanced high-density lipoproteins. Nature. 1989 Nov 23; 342(6248):448?1. [PubMed: 2586614]NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptClin Pharmacokinet. Author manuscript; readily available in PMC 2014 August 01.Mohammadpour and AkhlaghiPage28. Inazu A, Brown ML, Hesler CB, et al. Enhanced high-density lipoprotein levels triggered by a popular cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990 Nov 1; 323(18): 1234?.PMID:28038441 [PubMed: 2215607] 29. Boekholdt SM, Thompson JF. All-natural genetic variation as a tool in understanding the part of CETP in lipid levels and illness. J Lipid Res. 2003 Jun; 44(6):1080?3. [PubMed: 12639975] 30. Ridker PM, Pare G, Parker AN, et al. Polymorphism in the CETP gene area, HDL cholesterol, and danger of future myocardial infarction: Genomewide evaluation amongst 18 245 initially healthful girls from the Women’s Genome Overall health Study. Circ Cardiovasc Genet. 2009 Feb; 2(1):26?three. [PubMed: 20031564] 31. Wolk R, Chen D, Clark RW, et al. Pharmacokinetic, pharmacodynamic, and security profile of a brand new cholesteryl ester transfer protein inhibitor in healthful human subjects. Clin Pharmacol Ther. 2009 Oct; 86(four):430?. [PubMed: 19587642] 32. Dalvie D, Chen W, Zhang C, et al. Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos. 2008 Nov; 36(11): 2185?8. [PubMed: 18694908] 33. Prakash C, Chen W, Rossulek M, et al. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torc.